Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks.

Cabaletta spun out of University of Pennsylvania in 2017 with exclusive global rights to the autoimmune applications of the university’s CAR T technology. Its chimeric autoantibody receptor (CAAR)-mediated cell therapies are autologous T cells that are identical to CD19 CAR Ts in most respects; but instead of a CD19 antibody, the CAAR T cells express an autoantigen on their surfaces. ...